Global $80 Billion Cancer Immunotherapy Market to 2022

Dublin, Oct. 26, 2017 -- The "Global Cancer Immunotherapy Market Analysis & Forecast to 2022" report has been added to Research and Markets' offering.

"Global & USA Cancer Immunotherapy Market Analysis to 2020 reveals that the cancer immunotherapy space will be a significant revenue generator (excess of $80 billion) for the biopharmaceutical industry by 2020. The market has been supported by the approval of Bristol-Myers' Yervoy drug for melanoma, BMS's Opdivo and Merck's Keytruda.

Over the next decade, immunotherapies will be the backbone of cancer treatments in 60% of cancer types. It is forecast that by 2020, Avastin, Nivolumab, Revlimid, Rituxan and Xtandi will be the top five cancer drugs. A single drug, Bristol-Myers Squibb's Yervoy, for example has earned revenues of about $960 million in 2013 and it is expected to have a market value of $1,775.2 million in 2020. Industry Experts have predicted that Keytruda and Opdivo will generate sales revenues of $2.9 billion and $4.3 billion respectively in 2019.

The CAR-T industry is addressing unmet needs in specific relapsed cancers, however does early clinical trial data support a blockbuster status for this upcoming therapy? Some patients do indeed show long term activity and high remission rates, but there is a large proportion of patients with toxicities such as cytokine release syndrome and neurotoxicity. The main players within the CAR-T market are Juno Therapeutics, Kite Pharma, Novartis and Cellectis. The market is moving ahead, backed by years of R&D, from both academia and industry, investors capitol and small clinical studies. From 2017, Kelly Scientific forecasts that CAR T therapy will become more streamlined, with faster manufacturing times as advances in technologies take hold and clinical trials provide more robust evidence that this immunotherapy is robust. These factors, plus strategies to reduce adverse reactions and toxicities and larger players like Novartis taking stage will push CAR T therapy ahead. However, recent deaths in the Juno ROCKET trial are creating questions amongst investors. How will the CAR T space influence the total immunotherapy industry going forward? This comprehensive report scrutinizes the total market and provides cutting-edge insights and analysis.

An unmet need in the cancer therapy market has paved the way for immunotherapies and has increased patient survival rates significantly indicates Dr Deirdre Kelly, Owner of KellySciPub.com, Today significant therapeutic interest into ADC's, checkpoint inhibitors, cancer vaccines and anti-PD-1/PD-L1 agents are taking the market by storm, and we forecast vertical growth in this area within the next decade'. Therefore it is no wonder that most science journals have hailed cancer immunotherapy as a significant breakthrough treatment.

The interest on ADCs can be seen with the recent approvals of Adcetris (brentuximab vedotin) and Kadcyla (ado-trastuzumab emtansine). Currently, More than 15 companies are developing 30 different ADCs targeting both hematologic malignancies and solid tumors. ADCs represent a novel class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. As the ADCs carry a chemotherapy drug, they are believed to be more efficient and effective in the treatment of a disease. Due to shrinking pipelines and increasing pressure from patent expirations, big pharmaco' recognized the vaccine market as a potential resource for investors. Cancer vaccines have been found to earn a higher profit than the generic drugs, owing to the nature of the disease and the urgency in the demand for these vaccines. The global market for cancer vaccines was worth about $4.4 billion and it is likely to reach $8.4 billion in 2020.

Key Topics Covered:

1. Cancer Immunotherapy: An Overview
2. Current Status of Cancer Immunotherapy: An Overview
3. Challenges in Cancer Medicine Research: An Overview
4. Cancer Immunotherapeutic Products: An Overview
5. Available Immunotherapies for Cancer by Disease Type: An Overview
6. Cancer Incidence and Mortality: An Overview
7. Market Analysis
8. Market for Cancer Immunotherapy
9. Company Profiles
10. Cancer Immunotherapy Market Participants by Product Segment
11. CAR T Therapy
12. Regulations Pertaining to Immunotherapy Regulation in the USA
13. Regulations for Immunotherapy in Japan
14. European Regulation and Immunotherapeutics
15. Manufacturing of Immunotherapies
16. Supply Chain & Logistics
17. Pricing & Cost Analysis
18. Current Deals Within the CAR T Market
19. CAR T Therapy Company Case Studies

Companies Mentioned

• A. Menarini Industrie Farmaceutiche Riunite Srl
• Antigen Express Inc
• Celldex Therapeutics
• Dendreon Corp.
• EMD Serono Inc
• Eli Lilly and Co.
• Genentech Inc
• Genmab AS
• GlaxoSmithKline
• Gliknik Inc
• GlobeImmune Inc
• Heat Biologics Inc
• Immatics Biotechnologies GmbH
• Kite Pharma Inc
• MabVax Therapeutics Holdings Inc
• MedImmune LLC
• Merck & Co., Inc
• Morphotek Inc
• NewLink Genetics Corp.
• Northwest Biotherapeutics Inc
• NovaRx Corp.
• OSE Pharma SA
• OncoPep Inc
• Oncothyreon Inc
• Oxford BioTherapeutics Ltd.
• Pique Therapeutics
• Regen Biopharma Inc
• Roche Holdings Inc
• TapImmune Inc
• ThioLogics Ltd.
• Transgene SA
• Vaccinogen Inc
• Viventia Biotechnologies Inc
• Wilex AG
• Ziopharm Oncology Inc

For more information about this report visit https://www.researchandmarkets.com/research/g78qt8/global_cancer

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Oncology Drugs